Stephan Winklmeier

Stephan Winklmeier

Auto-generated profile, based on publicly available information

Stephan Winklmeier

Institute of Clinical Neuroimmunology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2023 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
AKArek Kendirli
Arek Kendirli
CRClara de la Rosa
Clara de la Rosa
KLKatrin F. Lämmle
Katrin F. Lämmle
KEKlara Eglseer
Klara Eglseer
IBIsabel J. Bauer
Isabel J. Bauer
NKNaoto Kawakami
Naoto Kawakami
Multiple sclerosis (MS) involves the infiltration of autoreactive T cells into the CNS, yet we lack a comprehensive understanding of the signaling pathways that regulate this process. Here, we conducted a genome-wide in vivo CRISPR screen in a rat MS model and identified 5 essential brakes and 18 essential facilitators of T cell migration to the CNS. While the transcription factor ETS1 limits entry to the CNS by controlling T cell responsiveness, three functional modules, centered around the adhesion molecule α4-integrin, the chemokine receptor CXCR3 and the GRK2 kinase, are required for CNS migration of autoreactive CD4+ T cells. Single-cell analysis of T cells from individuals with MS confirmed that the expression of these essential regulators correlates with the propensity of CD4+ T cells to reach the CNS. Our data thus reveal key regulators of the fundamental step in the induction of MS lesions.

1 August 2019 in Journal of Autoimmunity
Verified
Journal Article
Closed access
MBMattias Bronge
Mattias Bronge
SRSabrina Ruhrmann
Sabrina Ruhrmann
CCClaudia Carvalho-Queiroz
Claudia Carvalho-Queiroz
ONOla B. Nilsson
Ola B. Nilsson
AKAndreas Kaiser
Andreas Kaiser
HGHans Grönlund
Hans Grönlund

20 December 2021 in iScience
Verified
Journal Article
Open access
SWStephan Winklmeier
Stephan Winklmeier
KEKatharina Eisenhut
Katharina Eisenhut
DTDamla Taskin
Damla Taskin
HRHeike Rübsamen
Heike Rübsamen
RGRamona Gerhards
Ramona Gerhards
EMEdgar Meinl
Edgar Meinl
Although some COVID-19 patients maintain SARS-CoV-2-specific serum immunoglobulin G (IgG) for more than 6 months postinfection, others eventually lose IgG levels. We assessed the persistence of SARS-CoV-2-specific B cells in 17 patients, 5 of whom had lost specific IgGs after 5–8 months. Differentiation of blood-derived B cells in vitro revealed persistent SARS-CoV-2-specific IgG B cells in all patients, whereas IgA B cells were maintained in 11. Antibodies derived from cultured B cells blocked binding of viral receptor-binding domain (RBD) to the cellular receptor ACE-2, had neutralizing activity to authentic virus, and recognized the RBD of the variant of concern Alpha similarly to the wild type, whereas reactivity to Beta and Gamma were decreased. Thus, differentiation of memory B cells could be more sensitive for detecting previous infection than measuring serum antibodies. Understanding the persistence of SARS-CoV-2-specific B cells even in the absence of specific serum IgG will help to promote long-term immunity.

21 March 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SMSimone Mader
Simone Mader
SHSamantha Ho
Samantha Ho
HWHoi Kiu Wong
Hoi Kiu Wong
SBSelia Baier
Selia Baier
SWStephan Winklmeier
Stephan Winklmeier
EMEdgar Meinl
Edgar Meinl
Autoantibodies against myelin oligodendrocyte glycoprotein (MOG) have recently been established to define a new disease entity, MOG-antibody-associated disease (MOGAD), which is clinically overlapping with multiple sclerosis. MOG-specific antibodies (Abs) from patients are pathogenic, but the precise effector mechanisms are currently still unknown and no therapy is approved for MOGAD. Here, we determined the contributions of complement and Fc-receptor (FcR)-mediated effects in the pathogenicity of MOG-Abs. Starting from a recombinant anti-MOG (mAb) with human IgG1 Fc, we established MOG-specific mutant mAbs with differential FcR and C1q binding. We then applied selected mutants of this MOG-mAb in two animal models of experimental autoimmune encephalomyelitis. First, we found MOG-mAb-induced demyelination was mediated by both complement and FcRs about equally. Second, we found that MOG-Abs enhanced activation of cognate MOG-specific T cells in the central nervous system (CNS), which was dependent on FcR-, but not C1q-binding. The identification of complement-dependent and -independent pathomechanisms of MOG-Abs has implications for therapeutic strategies in MOGAD.

14 April 2022 in Cells
Verified
Journal Article
Open access
PDF file
SPStefan Preisendörfer
Stefan Preisendörfer
YIYoshihiro Ishikawa
Yoshihiro Ishikawa
EHElisabeth Hennen
Elisabeth Hennen
SWStephan Winklmeier
Stephan Winklmeier
JSJonas C. Schupp
Jonas C. Schupp
Claudia A. Staab-WeijnitzClaudia A. Staab-Weijnitz
Claudia A. Staab-Weijnitz
Antibodies are central effectors of the adaptive immune response, widespread used therapeutics, but also potentially disease-causing biomolecules. Antibody folding catalysts in the plasma cell are incompletely defined. Idiopathic pulmonary fibrosis (IPF) is a fatal chronic lung disease with increasingly recognized autoimmune features. We found elevated expression of FK506-binding protein 11 (FKBP11) in IPF lungs where FKBP11 specifically localized to antibody-producing plasma cells. Suggesting a general role in plasma cells, plasma cell-specific FKBP11 expression was equally observed in lymphatic tissues, and in vitro B cell to plasma cell differentiation was accompanied by induction of FKBP11 expression. Recombinant human FKBP11 was able to refold IgG antibody in vitro and inhibited by FK506, strongly supporting a function as antibody peptidyl-prolyl cis-trans isomerase. Induction of ER stress in cell lines demonstrated induction of FKBP11 in the context of the unfolded protein response in an X-box-binding protein 1 (XBP1)-dependent manner. While deficiency of FKBP11 increased susceptibility to ER stress-mediated cell death in an alveolar epithelial cell line, FKBP11 knockdown in an antibody-producing hybridoma cell line neither induced cell death nor decreased expression or secretion of IgG antibody. Similarly, antibody secretion by the same hybridoma cell line was not affected by knockdown of the established antibody peptidyl-prolyl isomerase cyclophilin B. The results are consistent with FKBP11 as a novel XBP1-regulated antibody peptidyl-prolyl cis-trans isomerase and indicate significant redundancy in the ER-resident folding machinery of antibody-producing hybridoma cells.

1 May 2023 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
MBMichelle Biljecki
Michelle Biljecki
KEKatharina Eisenhut
Katharina Eisenhut
EBEduardo Beltrán
Eduardo Beltrán
SWStephan Winklmeier
Stephan Winklmeier
SMSimone Mader
Simone Mader
FTFranziska S. Thaler
Franziska S. Thaler
Background and Objectives Antibodies (Abs) against the cytoplasmic protein glutamic acid decarboxylase 65 (GAD65) are detected in patients with neurologic syndromes together referred to as GAD65-Ab spectrum disorders. The response of some of these patients to plasma exchange or immunoglobulins indicates that GAD65-Abs could contribute to disease pathogenesis at least at some stages of disease. However, the involvement of GAD65-reactive B cells in the CNS is incompletely understood. Methods We studied 7 patients with high levels of GAD65-Abs and generated monoclonal Abs (mAbs) derived from single cells in the CSF. Sequence characteristics, reactivity to GAD65, and the role of somatic hypermutations of the mAbs were analyzed. Results Twelve CSF-derived mAbs were generated originating from 3 patients with short disease duration, and 7/12 of these mAbs (58%) were GAD65 reactive in at least 1 detection assay. Four of 12 (33%) were definitely positive in all 3 detection assays. The intrathecal anti-GAD65 response was polyclonal. GAD65-Abs were mostly of the IgG1 subtype and had undergone affinity maturation. Reversion of 2 GAD65-reactive mAbs to their corresponding germline-encoded unmutated common ancestors abolished GAD65 reactivity. Discussion GAD65-specific B cells are present in the CNS and represent a sizable fraction of CSF B cells early in the disease course. The anti-GAD65 response in the CSF is polyclonal and shows evidence of antigen-driven affinity maturation required for GAD65 recognition. Our data support the hypothesis that the accumulation of GAD65-specific B cells and plasma cells in the CSF is an important feature of early disease stages.